Novartis to Buy Biotech Excellergy for Up to $2 Billion
By Adria Calatayud
Novartis said it agreed to buy Excellergy for up to $2 billion, bulking up its immunology portfolio with a biotech company that specializes in treatments for food allergy and other diseases.
The Swiss pharmaceutical company said Friday that the deal for privately-held Excellergy will add a drug candidate in early-stage trials with potential to complement its existing allergy portfolio.
The deal follows Novartis's agreement last week to buy a breast-cancer drug candidate from Synnovation Therapeutics for up to $3 billion, as the company turns to dealmaking to fill its pipeline and offset patent expirations.
Novartis said the acquisition builds on its long-standing presence in allergic disease.
The lead drug in Excellergy's portfolio is a so-called anti-IgE antibody. Novartis said the drug offers a differentiated mechanism that, if confirmed clinically, could support earlier symptom relief, stronger disease control and more convenient dosing across food allergy, hives, allergic asthma and other diseases.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
March 27, 2026 02:36 ET (06:36 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
5 Stocks to Buy Trading at Big Discounts
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
United States